“Drug Survival of Risankizumab Vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s695. https://doi.org/10.25251/m10xva58.